Lineage Cell Therapeutics (LCTX) Preferred Shares (2014 - 2015)
Lineage Cell Therapeutics (LCTX) reported Preferred Shares of $3.5 million for Q2 2015, little changed on a YoY basis from $3.5 million in Q2 2014, and little changed quarter-over-quarter from $3.5 million in Q1 2015.
Lineage Cell Therapeutics (LCTX) Preferred Shares (2014 - 2015) Analysis & Trends
Lineage Cell Therapeutics has reported Preferred Shares for 2 years, with the latest figure at $3.5 million in Q2 2015.
- For the quarter ending Q2 2015, Preferred Shares changed 0.0% year-over-year to $3.5 million; the trailing twelve-month figure through Jun 2015 stood at $3.5 million (changed 0.0% YoY), and the FY2014 full-year result was $3.5 million, changed N/A from the prior year.
- Preferred Shares for Q2 2015 stood at $3.5 million, roughly flat from $3.5 million in the prior quarter.
- The five-year high for Preferred Shares was $3.5 million in Q1 2014, with the low at $3.5 million in Q1 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Lineage Cell Therapeutics | 303.84 Mn | 239.94 Mn | 1.73 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2015 | 3.50 Mn |
| Mar 31, 2015 | 3.50 Mn |
| Dec 31, 2014 | 3.50 Mn |
| Sep 30, 2014 | 3.50 Mn |
| Jun 30, 2014 | 3.50 Mn |
| Mar 31, 2014 | 3.50 Mn |